Phase I Study of Colchicine Therapy in Childhood Hepatic Cirrhosis
This trial is active, not recruiting.
|Conditions||cirrhosis, liver cirrhosis|
|Sponsor||National Center for Research Resources (NCRR)|
|Collaborator||Children's Hospital Colorado|
|Start date||May 1990|
|Trial size||15 participants|
|Trial identifier||NCT00004368, 199/11947, CHD-1089|
I. Investigate the efficacy and safety of colchicine therapy in improving hepatic function and reducing hepatic fibrosis (scarring) in children with hepatic cirrhosis.
Male or female participants up to 17 years old.
- Advanced hepatic fibrosis or cirrhosis in children - Not pregnant
|Description||PROTOCOL OUTLINE: Patients receive colchicine orally twice daily for 24 months. After the first month, the dose of colchicine will increase and remain at that dose for the duration of study. Patients are evaluated every 6 months during study.|
Call for more information